home | about us | news & events | products | applications | contact   site map | toolbox | login
Click to perform your search
 
  news & events / press releases / 2006 index /
Press Release May 2006

SHIMADZU BIOTECH ENHANCES BIO-RESEARCH ANALYSES WITH NEW
AXIMA-TOF2

High-Energy MALDI CID MS/MS Instrumentation Delivers Greater Sensitivity, Flexibility

COLUMBIA, Md.
May 29, 2006

Shimadzu Biotech today introduced the AXIMA-TOF2, its new MALDI based high-performance TOF-TOF mass spectrometer. Representing the next generation in high-energy collision induced dissociation (CID) MS/MS instrumentation, the AXIMA-TOF2 brings enhanced flexibility to Life Science laboratories, significantly extending the type of analyses they can provide. The device was introduced today at the 54th American Society of Mass Spectrometry Conference in Seattle.

With Shimadzu Biotech's intuitive software bundled as standard, the AXIMA-TOF2 is ideal for use in open-access lab environments, delivering maximum results while requiring the minimum in user input. As a result, the system is equally robust and reliable whether employed by novices, or expert users, while the inclusion of industry standard XML data exporting allows it to integrate easily and seamlessly into any workflow.

Beyond its use in proteomics research, the AXIMA-TOF2 is equally adept at analyzing and processing polymers, oligonucleotides, SNPs, metabolites, lipids, carbohydrates or small molecules with extremely high sensitivity. "Using high-energy CID to augment fragmentation of analytes, Shimadzu Biotech's AXIMA-TOF2 mass spectrometer takes full advantage of the curved field reflectron technology, to deliver MS/MS data without the need for post-acceleration", says Dr. Emmanuel Raptakis, Product Manager for Shimadzu Biotech. "Ion scattering is minimized by utilizing a totally grid-less ion path and helium as the collision gas of choice. The instrument is designed to have the highest ion transmission possible, thus optimizing real-world sensitivity",

"The Axima-TOF2 high energy CID has proven to be invaluable for a multitude of applications ranging from performing high confidence protein identification to aiding de novo sequencing", says Dr Rachel Martin, Applications Manager for Shimadzu Biotech. "Analysis of a wide variety of compound classes, like lipids and carbohydrates, can yield invaluable structural information previously out of reach for lower energy MS/MS approaches".

The novel ion gating technology employed in the AXIMA-TOF2 affords industry-leading precursor ion isolation resolution, which allows the successful MS/MS analysis of the most challenging complex mixtures. The curved field reflectron technology, under license from Johns Hopkins University, MD, US, has been updated to enhance the sensitivity and quality of high energy CID MS/MS spectra.

The Axima TOF2 is designed to seamlessly integrate with the wide Shimadzu Biotech product portfolio, to offer complete solutions. Intuitive software allows the use of this device in an open access environment with minimal training, or within the most up-to-the-minute workflows, including automated PMF or MS-MS protein identification, LC-MALDI and others.

The AXIMA-TOF2 key benefits include:
  • Highest energy collisions (20keV laboratory-frame collisions)
  • Outstanding sensitivity
  • Optimal precursor ion selection
  • Manual or fully automated operation for seamless analysis
  • High-resolution MS data in reflectron mode for accurate peptide mass fingerprinting
  • Proteomics analysis capabilities
  • LC-MALDI software for precise identification of off-line separated complex mixtures via automated MS/MS and integrated database searching
The AXIMA-TOF2 comes with multiple software features including:
  • Proteomics Suite for single sample manual acquisition or fully automated data dependent peptide mass fingerprinting and MS/MS for protein identification with integrated Mascot® searching.
  • LC MALDI Integrated Package provides total support for LC MALDI-based experiments with fully automated acquisition, including an intensity map of all sample spots across the target to assess the distribution of peptides and identify the position of the apex of chromatographic peaks, compilation of 'candidate' list, automatic MS/MS and subsequent database searching.
  • Biomarker Recognition identifies biomarker patterns and distribution compounds of interest in clinical samples. Data can be easily exported into alternative processing packages.
  • Functional Genomics offers the user excellent linear mode performance that lends itself to alternative applications such as oligonucleotide and SNP analysis and QC processes.
  • QC Applications, with Launchpad™ software, includes a module offering fully automated QC analysis of large numbers of samples, complete with a user-defined report indicating the presence or absence of the target compound, an estimate of purity and known contaminants, and adducts or truncated/extended analogues.

-ends-

About Shimadzu Biotech

Shimadzu Biotech is a strategic global brand of Shimadzu Corporation. Shimadzu Biotech is focused on providing integrated solutions for life science and drug development to accelerate the progress of biotechnology in research and development. Shimadzu Biotech represents a new way of thinking in the health and life science sectors by combining a core competence in instrument design and manufacture together with strategic partnerships to advance the development of knowledge in biotechnology. Product offerings include mass spectrometry integrated with enabling technology for high throughput analysis (MALDI, LC/MS, automated systems for analyzing gels with mass spectrometry) and specific solutions for DNA analysis (ranging from UV spectroscopy to chip-based electrophoresis) among a range of other offerings.

For more information, please contact:

Shimadzu Biotech

Emmanuel Raptakis, Product Manager
Tel: +44-161-888-4400, ext 309
Fax: 44-161-888-4402
Email: emmanuel.raptakis@shimadzu-biotech.net

Rachel Martin, Applications Manager
Tel: +44-161-888-4400, ext 304
Fax: +44-161-888-4402
Email: rachel.martin@shimadzu-biotech.net

For press information, please contact:

De Facto Communications
Richard Anderson
Tel: 44-20-7496-3300
Fax: 44-20-7496-3355
Email: r.anderson@defacto.com

previous >> 2006 index >>  
 
   
To register for an account
please click here >>
To log in, enter your details below, then click "OK".
Username: (email address)
Password:
  OK Cancel


Forgotten your password? Enter your username above and then click Retrieve Password and the password will be emailed to the address supplied.
close
   
Sorry, this page cannot be emailed.
ok

   
e-mail page to a friend
Enter your friend's e-mail address in the box below (their address will not be retained or used for any other purpose).
Enter your name here.
Add your personal message in the box below.
Click OK to send your message, or Clear if you want to start again.
 
ok clear cancel

   
Sorry, there is no print-friendly version of this page. Please click OK to use your browser's normal print function.
 
ok cancel

   
contact us
Please enter your telephone number in the box below (your details will not be retained or used for any other purpose).
Please select your country;
Enter your email address.
Enter your name here.
Enter any message in the box below.
Click OK to send this contact request, or Clear if you want to start again.
 
ok clear cancel


  Privacy Policy